切换至 "中华医学电子期刊资源库"
高级检索
中华结直肠疾病电子杂志

中华结直肠疾病电子杂志 ›› 2016, Vol. 05 ›› Issue (02) : 159 -162. doi: 10.3877/cma.j.issn.2095-3224.2016.02.09

所属专题： 文献；

论著

FOLFOX和FOLFIRI方案用于大肠黏液腺癌辅助化疗的比较
刘山1, 孟令新1,†(), 张可1, 秦朝阳2, 王刚平3, 孟芹1, 丁兆军1   
  1. 1. 276826　日照市人民医院肿瘤科
    2. 276826　日照市人民医院胃肠外科
    3. 276826　日照市人民医院病理科
  • 收稿日期:2016-02-14 出版日期:2016-04-25
  • 通信作者: 孟令新
  • 基金资助:
    济宁医学院面上项目(JY2013KY061)

Comparison of FOLFOX and FOLFIRI adjuvant chemotherapy regimens in the treatment of colorectal mucinous adenocarcinoma

Shan Liu1, Lingxin Meng1,†(), Ke Zhang1, Zhaoyang Qin2, Gangping Wang3, Qin Meng1, Zhaojun Ding1   

  1. 1. Department of Oncology, Rizhao People′s Hospital, Rizhao 276826, China
    2. Department of Gastrointestinal Surgery, Rizhao People′s Hospital, Rizhao 276826, China
    3. Department of Pathology, Rizhao People′s Hospital, Rizhao 276826, China
  • Received:2016-02-14 Published:2016-04-25
  • Corresponding author: Lingxin Meng
  • About author:
    Corresponding author: Meng Lingxin, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

刘山, 孟令新, 张可, 秦朝阳, 王刚平, 孟芹, 丁兆军. FOLFOX和FOLFIRI方案用于大肠黏液腺癌辅助化疗的比较[J]. 中华结直肠疾病电子杂志, 2016, 05(02): 159-162.

Shan Liu, Lingxin Meng, Ke Zhang, Zhaoyang Qin, Gangping Wang, Qin Meng, Zhaojun Ding. Comparison of FOLFOX and FOLFIRI adjuvant chemotherapy regimens in the treatment of colorectal mucinous adenocarcinoma[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2016, 05(02): 159-162.

目的

探讨FOLFOX及FOLFIRI方案在大肠黏液腺癌术后辅助化疗中的疗效差异。

方法

将40例术后病理证实为大肠黏液腺癌患者随机分为2组，实验组应用FOLFIRI方案化疗，对照组应用FOLFOX方案化疗。比较两组的无进展生存时间（progression free survival，PFS），并应用Kaplan-Meier法进行生存率统计分析。

结果

FOLFOX组的中位PFS为13个月，FOLFIRI组的中位PFS为18个月。FOLFIRI方案组PFS比FOLFOX方案组PFS长5个月，差异有统计学意义（χ2=4.294，P=0.038）。

结论

对于大肠黏液腺癌，术后应用FOLFIRI方案化疗比FOLFOX方案可延长PFS。

关键词: 结直肠肿瘤, 治疗, 粘液腺癌, 辅助化疗
Objective

To evaluate the clinical effect of FOLFOX regimen and FOLFIRI regimen in the treatment of colorectal mucinous adenocarcinoma after operation.

Methods

40 patients confirmed mucinous adenocarcinoma by surgery and pathology were divided randomly into two groups. Twenty patients (Group FOLFOX) were treated with oxaliplatin combined with 5-fluorouracil, while the other Twenty patients (Group FOLFIRI) were treated with irinotecan combined with 5-fluorouracil. The progression free survival (PFS) of two groups was compared. Survival was estimated using the Kaplan-Meier method.

Results

The PFS of Group FOLFOX is 13 months, while the PFS of Group FOLFIRI is 18 months. Differences are statistically significant (χ2=4.294, P=0.038).

Conclusion

Colorectal mucinous adenocarcinoma after operation treated with FOLFIRI regimen can prolong PFS than FOLFOX regimen.

Key words: Colorectal neoplasms, Therapy, Mucinous adenocarcinoma, Adjuvant chemotherapy
表1 两组病例资料构成比表
组别 性别 肠癌部位 术后病理分期
男 女 直肠癌 结肠癌 II期 III期
FOLFOX组 14 6 16 4 4 16
FOLFIRI组 15 5 14 6 3 17
χ2 0.003 0.006 0.040
P值 0.72 1.00 0.68
表2 两组大肠黏液腺癌患者无进展生存时间表（月）
FOLFOX组 PFS 6 8 9 10 11 12 13 14 19 20 21 24 30 32 ?
例数 2 1 1 2 1 2 4 1 1 1 1 1 1 1
FOLFIRI组 PFS 9 11 12 14 15 16 17 18 19 20 21 25 29 33 36
例数 1 1 1 1 1 1 2 3 1 2 1 1 1 2 1
图1 两组患者无进展生存时间曲线图
[1]
Hyngstrom JR, Hu CY, Xing Y, et al. Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base.Ann Surg Oncol, 2012, 19(9): 2814-2821.
[2]
Hugen N, Verhoeven RH, Radema SA, et al. Prognosis and value of adjuvant chemotherapy in stage III mucinous colorectal carcinoma.Ann Oncol, 2013, 24(11): 2819-2824.
[3]
Consorti F, Lorenzotti A, Midiri G, et al. Prognostic significance of mucinous carcinoma of colon and rectum: a prospective case-control study. J Surg Oncol, 2000, 73(2): 70-74.
[4]
Hyngstrom JR, Hu CY, Xing Y, et al. Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base. Ann Surg Oncol, 2012, 19(9): 2814-2821.
[5]
Jivapaisarnpong P, Boonthongtho K.Clinicopathological characteristics of mucinous and non-mucinous adenocarcinoma in the colonand rectum in Rajavithi Hospital, Thailand.J Med Assoc Thai, 2011, 94(Suppl 2): S41-45.
[6]
Barresi V, Reggiani Bonetti L, Ieni A, et al. Prognostic significance of grading based on the counting of poorly differentiated clusters in colorectalmucinous adenocarcinoma. Hum Pathol, 2015, 46(11): 1722-1729.
[7]
Zamir N, Ahmed S, Akhtar J. Mucinous adenocarcinoma of colon.APSP J Case Rep, 2010, 1(2): 20.
[8]
Catalano V, Loupakis F, Graziano F, et al. Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer. Ann Oncol, 2012, 23(1): 135-141.
[9]
Kim SH, Shin SJ, Lee KY, et al. Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III coloncancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study. Ann Surg Oncol, 2013, 20(11): 3407-3413.
[10]
Negri FV, Wotherspoon A, Cunningham D, et al Norman AR. Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer. Ann Oncol, 2005, 16(8): 1305-1310.
[11]
Javier Martinez-Useros, Maria Rodriguez-Remirez, Aurea Borrero-Palacios, et al. DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer. BMC Cancer, 2014, 14: 965.
[12]
Oberholzer K, Menig M, Kreft A, et al. Rectal cancer: mucinous carcinoma on magnetic resonance imaging indicates poor response to neoadjuvant chemoradiation. Int J Radiat Oncol Biol Phys, 2012, 82(2): 842-848.
[13]
Cao Y, Jin ZX, Tong XP, et al. Synergistic effects of topoisomerase Iinhibitor, SN38, on Fas-mediated apoptosis. Anticancer Res, 2010, 30(10): 3911-3917.
[14]
Nöpel-Dünnebacke S, Schulmann K, Reinacher-Schick A, et al. Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy. Z Gastroenterol, 2014, 52(12): 1394-1401.
[1] 唐旭, 韩冰, 刘威, 陈茹星. 结直肠癌根治术后隐匿性肝转移危险因素分析及预测模型构建[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 16-20.
[2] 张生军, 赵阿静, 李守博, 郝祥宏, 刘敏丽. 高糖通过HGF/c-met通路促进结直肠癌侵袭和迁移的实验研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 21-24.
[3] 彭旭, 邵永孚, 李铎, 邹瑞, 邢贞明. 结肠肝曲癌的诊断和外科治疗[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 108-110.
[4] 马伟强, 马斌林, 吴中语, 张莹. microRNA在三阴性乳腺癌进展中发挥的作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 111-114.
[5] 陈垚, 徐伯群, 高志慧. 改良式中间上入路根治术治疗甲状腺癌的有效性安全性研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 619-622.
[6] 杨瑞洲, 李国栋, 吴向阳. 腹股沟疝术后感染的治疗方法探讨[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(06): 715-719.
[7] 倪文凯, 齐翀, 许小丹, 周燮程, 殷庆章, 蔡元坤. 结直肠癌患者术后发生延迟性肠麻痹的影响因素分析[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 484-489.
[8] 范小彧, 孙司正, 鄂一民, 喻春钊. 梗阻性左半结肠癌不同手术治疗方案的选择应用[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 500-504.
[9] 蓝冰, 王怀明, 王辉, 马波. 局部晚期结肠癌膀胱浸润的研究进展[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 505-511.
[10] 钟广俊, 刘春华, 朱万森, 徐晓雷, 王兆军. MRI联合不同扫描序列在胃癌术前分期诊断及化疗效果和预后的评估[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 378-382.
[11] 单秋洁, 孙立柱, 徐宜全, 王之霞, 徐妍, 马浩, 刘田田. 中老年食管癌患者调强放射治疗期间放射性肺损伤风险模型构建及应用[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 388-393.
[12] 陆志峰, 周佳佳, 梁舒. 虚拟现实技术在治疗弱视中的临床应用研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(08): 891-895.
[13] 李田, 徐洪, 刘和亮. 尘肺病的相关研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(08): 900-905.
[14] 岳瑞雪, 孔令欣, 郝鑫, 杨进强, 韩猛, 崔国忠, 王建军, 张志生, 孔凡庭, 张维, 何文博, 李现桥, 周新平, 徐东宏, 胡崇珠. 乳腺癌HER2蛋白表达水平预测新辅助治疗疗效的真实世界研究[J]. 中华临床医师杂志(电子版), 2023, 17(07): 765-770.
[15] 符梅沙, 周玉华, 李慧, 薛春颜. 淋巴细胞免疫治疗对复发性流产患者外周血T淋巴细胞亚群分布与PD1/PD-L1表达的影响及意义[J]. 中华临床医师杂志(电子版), 2023, 17(06): 726-730.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号